Barclays raised the firm’s price target on Summit Therapeutics (SMMT) to $16 from $13 and keeps an Underweight rating on the shares. The firm updated the company’s model to include colorectal cancer but says “key questions remain.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics Advances Ivonescimab Development Amid Financial Growth
- Summit Therapeutics Launches New Phase III Study
- Summit Therapeutics price target lowered to $32 from $33 at Clear Street
- Morning Movers: Cleveland-Cliffs surges following earnings report
- Options Volatility and Implied Earnings Moves Today, October 20, 2025